Audentes Therapeutics, Inc
BOLD
BOLD was delisted on the 14th of January, 2020.
89 hedge funds and large institutions have $768M invested in Audentes Therapeutics, Inc in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 35 increasing their positions, 19 reducing their positions, and 12 closing their positions.
84% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 19
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
16% more capital invested
Capital invested by funds: $660M → $768M (+$107M)
10% more funds holding
Funds holding: 81 → 89 (+8)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.3M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$26.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$8.83M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$8.78M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$6.28M |
Top Sellers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$31.6M |
| 2 |
VVM
Versant Venture Management
San Francisco,
California
|
-$16.5M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$9.88M |
| 4 |
DM
Deerfield Management
New York
|
-$9.19M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$4.16M |
BOLD Hedge Fund Activity: Q4 2017 in Review
89 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Audentes Therapeutics, Inc (BOLD) for Q4 2017, worth a combined $768M — up 16% from $660M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new BOLD positions and 12 closed out — a net gain of 8 holders — while 35 added to existing stakes and 19 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $31.3M. The largest seller was Adage Capital Partners, cutting an estimated $31.6M.
- 89 institutional investors held Audentes Therapeutics, Inc (BOLD) as of Q4 2017, up from 81 in Q3 2017.
- Funds reported $768M of Audentes Therapeutics, Inc stock for Q4 2017, up 16% quarter-over-quarter.
- 20 funds opened new Audentes Therapeutics, Inc positions in Q4 2017 and 12 closed out, a net change of +8 holders.
- The largest Audentes Therapeutics, Inc buyer in Q4 2017 was Fidelity Investments, an estimated $31.3M added.
- The largest Audentes Therapeutics, Inc seller in Q4 2017 was Adage Capital Partners, an estimated $31.6M sold.
Based on aggregated 13F filings for Q4 2017.